Sixty subjects will take part in this study. The subjects will be randomly assigned in a 1:1 ratio between the two arms of study. (Group A: Solution of Luffa Nasal Operculate 5mg/mL, Group B: saline).

The subjects will use the study medication or comparative, according to their randomization, for a treatment period of 3 to 7 days. A follow-up visit will be made 15 days after initiation of treatment.

Inclusion Criteria:

• Subjects of both sexes aged over 18 years.
• Presence of nasal congestion due to colds, rhinitis, influenza, sinusitis and acute or chronic sinusitis
• Sign the Informed Consent Form
• Comply the study requirements and attend to study visits
• Female subjects must have a NEGATIVE urine pregnancy test during the screening.

Exclusion Criteria:

• Known allergy to any study product component
• Subject pregnant, lactating or of childbearing potential and not using adequate and effective contraceptive
• Vasoconstrictor nasal topic or oral
• Use of a decongestant nasal whatever the route of administration
• Use of intranasal corticosteroids
• Use of antiallergic
• Use of medication containing atropine
• Subjects that are participating in another study or who participated in another study, less than 12 months
• Any subjects deemed unsuitable for study by the Principal Investigator
• Abuse of alcohol or illicit drugs